ALNA News and Press, Allena Pharmaceuticals Inc. From 03/07/19

Allena Pharmaceuticals (NASDAQ: ALNA ): Q4 GAAP EPS of -$0.46. More news on: Allena Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

-- Achieved Alignment with U.S. Food and Drug Administration (FDA) on Phase 3 URIROX TM Program and Accelerated Approval Strategy for Reloxaliase -- -- Phase 3 URIROX-1 and URIROX-2 Trials Ongoing; URIROX-1 Topline Data Expected in Second Half of 2019 -- -- Louis Brenner, M.D. Ap...

NEWTON, Mass., March 05, 2019 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, ...

Investment Thesis: Allena Pharmaceuticals ( ALNA ) is a clinical-stage biotech company which currently specializes in treating hyperoxaluria and hyperuricemia. We have previously suggested that the risks to the initiation of the Phase III clinical trial were too high for investment and had...